Skip to main content
SpringerLink
Log in

New Data on the Safety of Loratadine

  • Original Research Article
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

Since the European registration of loratadine, a significant amount of new and previously unpublished data have become available supporting the generally good tolerability profile of this nonsedating antihistamine. This report describes safety data obtained from more than 55 000 additional patients in open and controlled studies, and also describes information obtained from postmarketing surveillance data during the widespread use of this agent. These new data demonstrate that loratadine does not possess any significant CNS or anticholinergic effects and the side effects are comparable with those associated with placebo. Loratadine is apparently lacking in any unusual or serious effects and is well tolerated by a wide spectrum of patient populations, including the elderly and patients taking a variety of concomitant medications for concurrent illnesses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. European Journal of Clinical Pharmacology 32: 419–421, 1987

    Article  PubMed  CAS  Google Scholar 

  • Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37: 42–57, 1989

    Article  PubMed  CAS  Google Scholar 

  • Friedman HM. Loratadine: a potent, nonsedating, and long-acting H1 antagonist. American Journal of Rhinology 1: 95–99, 1987

    Article  Google Scholar 

  • Gaillard AWK, Gruisen A, de Jong R. The influence of antihistamines on human performance. European Journal of Clinical Pharmacology 35: 1–5, 1988

    Article  CAS  Google Scholar 

  • Herberg KW. Studie zur Fahrtuchtigkeit nach einnahme von Loratadin. Munchener Medizinische Wochenschrift 132: 463–467, 1990

    Google Scholar 

  • Hilbert R, Radwanski E, Weglein R, Luc V, Perentesis G, et al. The pharmacokinetics of loratadine in normal geriatric volunteers. Journal of International Medical Research 16: 50–60, 1988

    PubMed  CAS  Google Scholar 

  • Mann KV, Crowe JP, Tietze KJ. Nonsedating histamine H1-receptor antagonists. Clinical Pharmacy 8: 331–344, 1989

    PubMed  CAS  Google Scholar 

  • Meltzer EO. Evaluation of clemastine and a new antihistamine (loratadine) in patients with seasonal allergic rhinitis. 44th Annual Congress, American College of Allergists, Boston, November, 1987

  • Moser L, Plum H, Buckmann M. Lack of potentiation of the effect of alcohol by loratadine. 13th Congress of the European Academy of Allergology and Clinical Immunology, Budapest, May, 1986

  • Roth T, Roehrs T, Koshorek G, Sicklesteel J, Zorick F. Sedative effects of antihistamines. Journal of Allergy and Clinical Immunology 80: 94–98, 1987

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitair Ziekenhuis, Kliniek voor Neus-Keel-Oor-Ziekten, De Pintelaan, 185, B-9000, Gent, Belgium

    Paul B. Van Cauwenberge

Authors
  1. Paul B. Van Cauwenberge
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Cauwenberge, P.B. New Data on the Safety of Loratadine. Drug Invest 4, 283–291 (1992). https://doi.org/10.1007/BF03259406

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259406

Keywords

Search

Navigation